Stonepine Capital Management LLC Purchases 46,000 Shares of Indivior PLC $INDV

Stonepine Capital Management LLC raised its position in Indivior PLC (NASDAQ:INDV) by 15.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 350,000 shares of the company’s stock after buying an additional 46,000 shares during the quarter. Indivior comprises about 5.1% of Stonepine Capital Management LLC’s portfolio, making the stock its 5th largest holding. Stonepine Capital Management LLC’s holdings in Indivior were worth $5,159,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Amalgamated Bank acquired a new stake in shares of Indivior in the second quarter valued at approximately $61,000. Mirae Asset Global Investments Co. Ltd. grew its position in Indivior by 16.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock valued at $71,000 after purchasing an additional 666 shares in the last quarter. CTC Alternative Strategies Ltd. acquired a new stake in Indivior in the 1st quarter valued at $96,000. Prudential Financial Inc. acquired a new stake in Indivior in the 2nd quarter valued at $207,000. Finally, State of New Jersey Common Pension Fund D bought a new stake in Indivior during the 2nd quarter worth about $262,000. 60.33% of the stock is owned by institutional investors.

Indivior Stock Up 0.1%

Shares of Indivior stock opened at $34.02 on Thursday. The business has a fifty day simple moving average of $28.09 and a two-hundred day simple moving average of $21.65. Indivior PLC has a 1 year low of $7.62 and a 1 year high of $34.64.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.38 by $0.34. The firm had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. Indivior had a net margin of 9.83% and a negative return on equity of 90.79%. Sell-side analysts predict that Indivior PLC will post 1.22 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Morgan Stanley restated an “overweight” rating and issued a $36.00 price objective on shares of Indivior in a report on Wednesday. Craig Hallum restated a “buy” rating and issued a $41.00 price target on shares of Indivior in a research note on Friday, October 31st. Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 3rd. Northland Securities set a $40.00 price objective on Indivior in a report on Friday, October 31st. Finally, HC Wainwright boosted their target price on shares of Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Indivior has a consensus rating of “Buy” and an average price target of $32.71.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.